Moderna Inc [MRNA] stock Upgrade by HSBC Securities analyst, price target now $69

- Advertisements -

Moderna Inc [NASDAQ: MRNA] gained 3.04% or 2.25 points to close at $76.35 with a heavy trading volume of 3927620 shares. The company report on November 14, 2023 at 7:00 AM that Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023.

Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Moderna’s ESG Investor Event will include presentations from management on Moderna’s ESG strategy.

It opened the trading session at $74.46, the shares rose to $78.30 and dropped to $74.21, the range by which the price of stock traded the whole day. The daily chart for MRNA points out that the company has recorded -39.20% loss over the past six months. However, it is still -22.06% lower than its most recent low trading price.

- Advertisements -

If we look at the average trading volume of 4.31M shares, MRNA reached to a volume of 3927620 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Moderna Inc [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $134.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.24. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

HSBC Securities have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 03, 2023.

- Advertisements -

The Average True Range (ATR) for Moderna Inc is set at 4.25, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.21. The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 19.86.

Trading performance analysis for MRNA stock

Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.02. With this latest performance, MRNA shares dropped by -11.56% in over the last four-week period, additionally sinking by -39.20% over the last 6 months – not to mention a drop of -57.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 44.17, with the RSI for the last a single of trading hit 51.11, and the three-weeks RSI is set at 41.09 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 91.30, while it was recorded at 72.04 for the last single week of trading, and 122.83 for the last 200 days.

Moderna Inc [MRNA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc [MRNA] shares currently have an operating margin of +48.49 and a Gross Margin at +69.84. Moderna Inc’s Net Margin is presently recorded at +43.76.

Return on Total Capital for MRNA is now 52.37, given the latest momentum, and Return on Invested Capital for the company is 47.81. Return on Equity for this stock inclined to 50.27, with Return on Assets sitting at 32.82. When it comes to the capital structure of this company, Moderna Inc [MRNA] has a Total Debt to Total Equity ratio set at 6.28. Additionally, MRNA Total Debt to Total Capital is recorded at 5.90, with Total Debt to Total Assets ending up at 4.60. Long-Term Debt to Equity for the company is recorded at 5.25, with the Long-Term Debt to Total Capital now at 4.94.

Reflecting on the efficiency of the workforce at the company, Moderna Inc [MRNA] managed to generate an average of $2,144,103 per employee. Receivables Turnover for the company is 7.71 with a Total Asset Turnover recorded at a value of 0.75.Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.35 and a Current Ratio set at 2.46.

An analysis of Institutional ownership at Moderna Inc [MRNA]

The top three institutional holders of MRNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in MRNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in MRNA stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *